Survival Patterns in Early-onset Colorectal Cancer Receiving Adjuvant Capecitabine Based Therapy
Makaleler > Tam Makale · 2026
Yazarlar: Oğuzcan ÖZKAN, Aslı GEÇGEL, Zeynep Sıla GÖKDERE, Barış EMEKDAŞ, Hasan Çağrı YILDIRIM
Journal of Oncological Sciences, Uluslararası, Scopus, 2026
DOI: 10.37047/jos.galenos.2026.2025-11-8
Özet
Objective: The incidence of early-onset colorectal cancer (EOCRC) is increasing worldwide, yet optimal adjuvant treatment strategies remain unclear.This study evaluated survival outcomes and prognostic factors in EOCRC patients treated with adjuvant capecitabine-based chemotherapy. Material and Methods:This retrospective study included 51 patients aged younger than 50 years with high-risk stage II or stage III colorectal cancer who underwent curative surgery followed by capecitabine-based adjuvant therapy between 2017 and 2021.Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan-Meier curves and Cox regression models.Results: The median follow-up was 32 months.Stage III patients had significantly poorer OS and RFS than those of Stage II patients (p<0.05).In multivariate analysis, recurrence was the only independent predictor of OS [hazard ratio (HR)=12.45,p=0.002].For RFS, nodal status remained an independent prognostic factor (HR=0.032, p=0.006).Among stage II patients, the XELOX regimen was associated with a significantly different recurrence risk compared to capecitabine monotherapy (HR=14.87,p=0.038). Conclusion:In EOCRC, stage and nodal status are key prognostic determinants.Adjuvant therapy should be tailored to pathological risk rather than age alone, as XELOX may offer a recurrence benefit in selected stage II patients, whereas routine treatment intensification risks avoidable toxicity.